The Oncology Institute, Inc. (NASDAQ:TOI) Major Shareholder Sells $25,530.18 in Stock

The Oncology Institute, Inc. (NASDAQ:TOIGet Free Report) major shareholder Havencrest Healthcare Partners sold 11,986 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $2.13, for a total transaction of $25,530.18. Following the completion of the sale, the insider now owns 68,014 shares in the company, valued at approximately $144,869.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Havencrest Healthcare Partners also recently made the following trade(s):

  • On Monday, January 22nd, Havencrest Healthcare Partners sold 10,263 shares of Oncology Institute stock. The stock was sold at an average price of $2.12, for a total transaction of $21,757.56.

Oncology Institute Trading Down 4.1 %

Shares of TOI stock opened at $2.08 on Friday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.34 and a current ratio of 4.71. The Oncology Institute, Inc. has a 12-month low of $0.33 and a 12-month high of $2.65. The firm’s 50 day moving average is $1.85 and its 200 day moving average is $1.51.

Oncology Institute (NASDAQ:TOIGet Free Report) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Oncology Institute had a negative return on equity of 61.02% and a negative net margin of 23.82%. The business had revenue of $82.04 million during the quarter, compared to the consensus estimate of $74.66 million. On average, equities analysts expect that The Oncology Institute, Inc. will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TOI. American International Group Inc. bought a new stake in shares of Oncology Institute during the 2nd quarter valued at $44,000. Bank of America Corp DE bought a new stake in shares of Oncology Institute during the 1st quarter valued at $69,000. JPMorgan Chase & Co. raised its position in shares of Oncology Institute by 2,410.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,041 shares of the company’s stock valued at $51,000 after purchasing an additional 9,641 shares during the period. California State Teachers Retirement System increased its holdings in Oncology Institute by 71.0% in the 3rd quarter. California State Teachers Retirement System now owns 13,734 shares of the company’s stock valued at $64,000 after acquiring an additional 5,703 shares during the last quarter. Finally, Northern Trust Corp bought a new stake in Oncology Institute in the 1st quarter valued at $129,000. 23.46% of the stock is currently owned by institutional investors.

About Oncology Institute

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services.

Further Reading

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.